Human immunodeficiency virus type 1 Gag, Pol, Env, Tat, Rev, and Vpu proteins (HIV-1 Gag-Pol-Env-Tat-Rev-Vpu)

The HIV-1 Gag, Pol, Env, Tat, Rev, and Vpu proteins constitute the essential structural, enzymatic, and regulatory components of the Human Immunodeficiency Virus type 1 (HIV-1) (NIH, 2023). Gag is responsible for the assembly and release of virus-like particles, while Pol encodes the critical enzymes reverse transcriptase, protease, and integrase, which are the primary targets for most antiretroviral drugs (UniProt, 2024). The Env protein (gp120/gp41) mediates viral attachment and fusion with host CD4+ cells, serving as a target for entry inhibitors (PubMed, 2022). Tat and Rev are essential regulatory proteins that control viral gene expression and mRNA transport, respectively, while Vpu facilitates viral budding and downregulates host immune receptors (NCBI, 2023). Collectively, these proteins drive the viral life cycle, leading to the depletion of CD4+ T cells and the progression to Acquired Immunodeficiency Syndrome (AIDS) (WHO, 2023). Therapeutic strategies often involve Highly Active Antiretroviral Therapy (HAART) to simultaneously inhibit multiple proteins within this group to prevent the emergence of drug-resistant strains (StatPearls, 2024).

Other names

HIV-1 structural and regulatory proteinsHIV-1 polyprotein complexHIV-1 genome productsHIV-1 proteome

Drugs targeting these proteins act by inhibiting reverse transcriptase (NRTIs/NNRTIs), preventing the cleavage of polyproteins by viral protease (PIs), blocking the integration of viral DNA into the host genome (INSTIs), or interfering with viral entry, fusion, and capsid assembly (HIV.gov, 2024; PubMed, 2023).